Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Часто задаваемые вопросы
В каком секторе работает Adagene Inc (ADAG)?
Adagene Inc относится к сектору Здравоохранение.
Какова текущая цена акций Adagene Inc (ADAG)?
По последним данным, цена акций Adagene Inc составляет 3,17 $, предыдущее закрытие — 2,97 $. За последнюю торговую сессию акции Adagene Inc выросли на 0,20 $, что соответствует росту на 6,73%.
Выплачивает ли Adagene Inc (ADAG) дивиденды?
Нет, Adagene Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Adagene Inc (ADAG)?
У компании Adagene Inc бета 0.563, что указывает на более низкую волатильность по сравнению с рынком в целом.
